LONDON (Alliance News) - GlaxoSmithKline PLC on Thursday said the Atlas and Flair studies showed that along-acting, injectable two-drug regimen in HIV-1 patients had similar efficacy to a daily three-drug treatment.
Both phase three studies assessed a long-acting, injectable combination of cabotegravir and rilpivirine - injected every four weeks - and compared it against a standard of care, daily, three-drug regimen.
48-week data from both studies shows that they met their primary endpoints, showing that the two-drug regimen was not inferior in treating HIV.
The two-drug regimen was developed by ViiV Healthcare, a specialist HIV company established by Glaxo and Pfizer Inc that also includes Shionogi & Co Ltd.
John Pottage, chief scientific & medical officer Of ViiV Healcare said: "With Flair and Atlas, we now have positive results from two pivotal phase three studies demonstrating that this long-acting, once-monthly injectable regimen has similar efficacy, safety and tolerability to a daily oral three-drug regimen for the treatment of HIV."
"We are also encouraged by patient preference data showing that nearly all participants who switched to the long-acting injectable regimen preferred it over their prior oral therapy. If approved, this two-drug regimen would give people living with HIV one month between each dose of antiretroviral therapy, changing HIV treatment from 365 dosing days per year, to just 12. We look forward to submitting applications to regulatory authorities later this year."
Glaxosmithkline (GSK)